Leah Anderson Gaffney

Leah Anderson Gaffney has extensive experience in the biotechnology and pharmaceutical industry. Leah is currently working at Vir Biotechnology, Inc. as the Director of Clinical Research since August 2022. Before that, they held the position of Associate Director of Clinical Research from June 2021 to August 2022.

Prior to joining Vir Biotechnology, Gaffney worked at Merck for several years. Their roles at Merck included Associate Principal Scientist, Clinical Scientist from May 2017 to June 2021, Sr. Scientist, Clinical Scientist from January 2015 to May 2017, Director of Medical Affairs for HIV and HCV from January 2014 to January 2015, and Clinical Science Liaison for Infectious Diseases from July 2011 to December 2013. In these various positions, they developed and maintained professional relationships with scientific thought leaders, facilitated peer-to-peer discussions, provided accurate scientific and medical information, and supported research programs.

Gaffney started their career in 2008 as a Postdoctoral Fellow at Novartis, where they conducted research on anti-viral mechanisms of action and identified novel targets for clinical compounds.

Overall, Gaffney's work experience demonstrates their expertise in clinical research, medical affairs, and infectious diseases within the biotechnology and pharmaceutical industry.

Leah Anderson Gaffney holds a PhD in microbial pathogenesis and immunology from Northwestern University - The Feinberg School of Medicine, which they obtained from 2002 to 2008. Prior to that, they completed their undergraduate studies at Rochester Institute of Technology, earning a BS degree in biotechnology from 1998 to 2002.